Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 6:37 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 865–888 of 2,083 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Neoadjuvant therapy Clear all

Conditions: Breast Cancer
Interventions: Paclitaxel, Carboplatin, Sunitinib; Drug
Lead sponsor: SCRI Development Innovations, LLC; Other
Eligibility: 18 Years and older · Female only
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 14
States / cities: Fort Lauderdale, Florida • Fort Myers, Florida • Gainesville, Georgia + 9 more

Conditions: Metastatic Melanoma
Interventions: Biochemo + bevacizumab then ipilimumab; Drug
Lead sponsor: California Pacific Medical Center Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Cancer; Chemotherapy
Interventions: COVID antibody titers in the blood; Other
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Colon Cancer
Interventions: PalloV-CC; Biological
Lead sponsor: George E. Peoples; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Triple Negative Breast Cancer
Interventions: Cisplatin, Paclitaxel; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 20
States / cities: Birmingham, Alabama • Indianapolis, Indiana • Baltimore, Maryland + 16 more

Conditions: Clear Cell Renal Cell Carcinoma
Interventions: Axitinib Oral Tablet [Inlyta]; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 2
States / cities: La Jolla, California • Cleveland, Ohio

Conditions: Castrate Sensitive Prostate Cancer
Interventions: goserelin, Enzalutamide, Abiraterone, 18F-DCFPyL, Prednisone, Radical Prostatectomy; Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 99 Years · Male only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Melanoma
Interventions: ipilimumab; Drug
Lead sponsor: Diwakar Davar; Other
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2017
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Ductal Breast Carcinoma In Situ, HER2/Neu Positive
Interventions: Laboratory Biomarker Analysis, Lapatinib Ditosylate, Placebo; Other · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 21 Years and older · Female only
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 2
States / cities: Birmingham, Alabama • Houston, Texas

Conditions: Breast Cancer
Interventions: Docetaxel, Carboplatin; Drug
Lead sponsor: Mothaffar Rimawi; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2025
U.S. locations: 3
States / cities: Cincinnati, Ohio • Houston, Texas

Conditions: Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma
Interventions: Biospecimen Collection, Breast Biopsy Procedure, Carboplatin, Cyclophosphamide, Darolutamide, Doxorubicin, Epirubicin, Magnetic Resonance Imaging, Paclitaxel, Pembrolizumab, Surgical Procedure, Ultrasound Imaging; Procedure · Drug · Biological
Lead sponsor: Vandana Abramson; Other
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2033
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Lung Non-Small Cell Carcinoma
Interventions: Chemotherapy, Immunotherapy, Intensity-Modulated Radiation Therapy, Computed Tomography, Magnetic Resonance Imaging, Fludeoxyglucose F-18, Biospecimen Collection; Drug · Other · Radiation + 1 more
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2036
U.S. locations: 125
States / cities: Jonesboro, Arkansas • Los Angeles, California • Parker, Colorado + 95 more

Conditions: Anatomic Stage III Breast Cancer AJCC v8, Locally Advanced Breast Carcinoma
Interventions: Contrast-Enhanced Ultrasound, Perflutren Lipid Microspheres, Ultrasound; Procedure · Drug
Lead sponsor: Kibo Nam; Other
Eligibility: 21 Years and older · Female only
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 3
States / cities: Rochester, Minnesota • Philadelphia, Pennsylvania • Dallas, Texas

Conditions: Prostate Cancer
Interventions: Ad-REIC/Dkk-3; Biological
Lead sponsor: Momotaro-Gene Inc.; Industry
Eligibility: 20 Years to 75 Years · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 1
States / cities: New York, New York

Conditions: NSCLC Stage II, NSCLC, Stage III
Interventions: Precision Exercise Regimen for Cancer Care (PERCC); Other
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 2
States / cities: Galveston, Texas • Salt Lake City, Utah

Conditions: Breast Cancer, Triple Negative Breast Cancer
Interventions: Everolimus; Drug
Lead sponsor: Jenny C. Chang, MD; Other
Eligibility: 18 Years and older · Female only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 3
States / cities: Houston, Texas • Sugar Land, Texas

Conditions: Localized Extraskeletal Ewing Sarcoma, Peripheral Primitive Neuroectodermal Tumor of Bone, Peripheral Primitive Neuroectodermal Tumor of Soft Tissues
Interventions: Cyclophosphamide, Dexrazoxane, Doxorubicin Hydrochloride, Etoposide, Ifosfamide, Laboratory Biomarker Analysis, Topotecan Hydrochloride, Vincristine Sulfate; Drug · Other
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 50 Years
Enrollment: 642 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2025
U.S. locations: 215
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 149 more

Conditions: Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
Interventions: Allogeneic Hematopoietic Stem Cell Transplantation, Cytarabine, Daunorubicin Hydrochloride, Idarubicin, Laboratory Biomarker Analysis, Vorinostat; Procedure · Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 754 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 441
States / cities: Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 302 more

Conditions: Cancer, Prostate Neoplasms
Interventions: Leuprolide or goserelin, Transdermal estradiol; Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older · Male only
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 2
States / cities: Seattle, Washington

Conditions: Melanoma Stage IIIB, Melanoma Stage IIIC, Melanoma Stage IIID
Interventions: Daromun, Surgery, Adjuvant therapy; Drug · Procedure
Lead sponsor: Philogen S.p.A.; Industry
Eligibility: 18 Years and older
Enrollment: 186 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2031
U.S. locations: 19
States / cities: Phoenix, Arizona • La Jolla, California • Orange, California + 16 more

Conditions: Breast Cancer
Interventions: PET (positron emission tomography); Procedure
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: Not listed
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2006
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Prostate Cancer
Interventions: Enoblituzumab, Standard of Care; Drug · Other
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older · Male only
Enrollment: 219 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 5
States / cities: Chicago, Illinois • Baltimore, Maryland • Minneapolis, Minnesota + 2 more

Conditions: Breast Neoplasm, Neoplasm Metastasis
Interventions: preoperative dose intense chemotherapy (FLAC/G-CSF); Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Female only
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1989 – 2002
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Chronic Lymphocytic Leukemia
Interventions: Bendamustine, Obinutuzumab; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 26
States / cities: Huntsville, Alabama • Mobile, Alabama • Chandler, Arizona + 22 more

Search by objective public record fields.

Neoadjuvant Sunitinib With Paclitaxel/Carboplatin in Patients With Triple-Negative Breast Cancer

Biochemotherapy and Bevacizumab Followed by Consolidation Therapy With Ipilimumab for Metastatic Melanoma

Immunological Responses of COVID-19 Vaccination

Trial of PalloV-CC in Colon Cancer

Cisplatin vs Paclitaxel for Triple Negative Breast Cancer

Prior Axitinib as a Determinant of Outcome of Renal Surgery

Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18FDCFPyL PET/CT in Newly Diagnosed Prostate Cancer

Immunogenicity and Biomarker Analysis of Neoadjuvant Ipilimumab for Melanoma

Lapatinib Ditosylate in Treating Patients With Ductal Breast Carcinoma In Situ

Neoadjuvant Carboplatin and Docetaxel in Triple Negative Breast Cancer

Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC

A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment

SHAPE Neoadjuvant Chemotherapy Response

Neoadjuvant Study of In-situ REIC/Dkk-3 in Prostate Cancer

PILOT for The Precision Exercise Regimen for Cancer Care (PERCC) Study

NECTAR Everolimus Plus Cisplatin in Triple (-) Breast Cancer

Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma

Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia

Neoadjuvant Estradiol or Androgen Deprivation in Clinically Localized Prostate Cancer

Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients

Molecular Marker Profiling of Axillary Lymph Nodes in Predicting Response in Patients With Locally Advanced or Metastatic Breast Cancer Who Are Undergoing Chemotherapy Followed By Surgery

Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer

Effect of Preoperative Chemotherapy on Axillary Lymph Node Metastases in Stage II Breast Cancer: A Prospective Randomized Trial

A Study of Obinutuzumab + Bendamustine (BG) in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL)